INSMED Inc.
- INSM ยท Nasdaq
- Pharmaceutical Preparations
- Bridgewater, NJ
- 1,664 employees
- CIK 0001104506
Updated from SEC filings through
Top things to know
Executives
- Will Lewis Chair and Chief Executive Officer of Insmed 8-K, 2026-10-29
-
William Lewis Chair and CEO 4, 2026-07-24 - Sara Bonstein Chief Financial Officer 4, 2026-06-05
- Roger Adsett Chief Operating Officer 4, 2026-08-12
- Martina Flammer M.D. Chief Medical Officer 4, 2026-08-07
- Michael Alexander Smith Chief Legal Officer 4, 2026-06-24
What leadership is saying
“The third quarter marked another period of meaningful progress, defined by commercial momentum, regulatory achievements, and advancement across our diversified pipeline”
Earnings press release (8-K Ex. 99.1), filed October 29, 2026
INSMED Inc is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Bridgewater, NJ. It trades as INSM on Nasdaq. Revenue was $606M in the fiscal year ending December 31, 2025, +66.7% from the year before. It reported about 1,664 employees. Will Lewis is Chair and Chief Executive Officer of Insmed.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $606M 10-K, 2026-02-19 | $364M 10-K, 2026-02-19 | $305M 10-K, 2026-02-19 | $245M 10-K, 2025-02-20 | $188M 10-K, 2024-02-22 |
| Operating income | -$1.2B 10-K, 2026-02-19 | -$878M 10-K, 2026-02-19 | -$710M 10-K, 2026-02-19 | -$457M 10-K, 2025-02-20 | -$375M 10-K, 2024-02-22 |
| SG&A | $701M 10-K, 2026-02-19 | $461M 10-K, 2026-02-19 | $345M 10-K, 2026-02-19 | $266M 10-K, 2025-02-20 | $234M 10-K, 2024-02-22 |
| Net income | -$1.3B 10-K, 2026-02-19 | -$914M 10-K, 2026-02-19 | -$750M 10-K, 2026-02-19 | -$482M 10-K, 2025-02-20 | -$435M 10-K, 2024-02-22 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Will Lewis Chair and Chief Executive Officer at Insmed Incorporated | Chair and Chief Executive Officer of Insmed | 8-K, 2026-10-29 |
| William Lewis | Chair and CEO | 4, 2026-07-24 |
| Sara Bonstein Chief Financial Officer at Insmed Incorporated | Chief Financial Officer | 4, 2026-06-05 |
| Roger Adsett | Chief Operating Officer | 4, 2026-08-12 |
| Martina Flammer M.D. Chief Medical Officer at Insmed Incorporated | Chief Medical Officer | 4, 2026-08-07 |
| Michael Alexander Smith | Chief Legal Officer | 4, 2026-06-24 |
| Michael Smith | Chief Legal Officer | 10-K, 2026-02-19 |
| S. Nicole Schaeffer | Chief People Strategy Officer | 10-K, 2026-02-19 |
| Orlov S. Nicole Schaeffer | Chief People Strategy Officer | 4, 2026-01-06 |
| Patrick Kevin Kane | Corporate Controller | 3, 2026-11-03 |
| Samuele Butera Leading for patients | SVP, GM, Global Respiratory | 4, 2026-06-24 |
| Elizabeth McKee Anderson | Director | 10-K, 2026-02-19 |
What INSMED Inc does
We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for commercial products, product candidates and technologies.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 219.4 million (as of October 23, 2026) | 10-Q, October 29, 2026 |
|---|---|---|
| Public float | $21.1B (as of June 30, 2025) | 10-K, February 19, 2026 |
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, October 29, 2026 |
| Latest proxy statement | Meeting May 13, 2026 (filed April 1, 2026) | DEF 14A, April 1, 2026 |
| Auditor | Ernst & Young LLP (Iselin, New Jersey) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| September 9, 2026 | David R. Brennan Director | Sale | 25,000 | $3.1M | Form 4, September 11, 2026 |
| August 17, 2026 | Melvin Sharoky Md Director | Sale | 5,000 | $638K | Form 4, August 19, 2026 |
| August 10, 2026 | Roger Adsett Chief Operating Officer | Sale | 239,850 | $32.0M | Form 4, August 12, 2026 |
| August 6, 2026 | Martina Flammer M.D. Chief Medical Officer | Sale | 27,173 | $3.5M | Form 4, August 7, 2026 |
| July 23, 2026 | William Lewis Chair and CEO | Sale | 10,700 | $1.1M | Form 4, July 24, 2026 |
| July 9, 2026 | William Lewis Chair and CEO | Sale | 10,699 | $1.3M | Form 4, July 10, 2026 |
| July 6, 2026 | Martina Flammer M.D. Chief Medical Officer | Sale | 12,302 | $1.4M | Form 4, July 8, 2026 |
| June 25, 2026 | William Lewis Chair and CEO | Sale | 21,398 | $2.2M | Form 4, June 26, 2026 |
Recent 8-K events
- 8-K filed 2026-10-29
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-10-20
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-10-05
- Item 5.02 Departure or appointment of directors or officers; compensation
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-07-16
- Item 7.01 Regulation FD disclosure
- 8-K filed 2026-05-15
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-07
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-04-07
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-03-23
- Item 7.01 Regulation FD disclosure
- Item 8.01 Other events
- 8-K filed 2026-02-19
- Item 2.02 Results of operations and financial condition (earnings release)
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about INSMED Inc
- What does INSMED Inc do?
- In its own words, from Item 1 of its 10-K: "We are a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Our commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare. To complement our internal research and development, we also actively evaluate in-licensing and acquisition opportunities for commercial products, product candidates and technologies."
- What is INSMED Inc's revenue?
- $606M for the fiscal year ending December 31, 2025, from its 10-K filed February 19, 2026.
- Is INSMED Inc profitable?
- INSMED Inc reported net income of -$1.3B for the fiscal year ending December 31, 2025.
- How many employees does INSMED Inc have?
- About 1,664 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of INSMED Inc?
- Will Lewis, Chair and Chief Executive Officer of Insmed, as named in a 8-K filed October 29, 2026.
- Who is the CFO of INSMED Inc?
- Sara Bonstein, Chief Financial Officer, as named in a 4 filed June 5, 2026.
- Where is INSMED Inc headquartered?
- Bridgewater, NJ.
- What is INSMED Inc's stock ticker?
- INSM on Nasdaq.
- What industry is INSMED Inc in?
- Pharmaceutical Preparations, SIC code 2834.
- What is INSMED Inc's website?
- insmed.com.
- When does INSMED Inc report earnings next?
- February 4, 2027. Source: estimate_8k_pattern.
- Is INSMED Inc a public company?
- Yes. INSMED Inc files with the SEC under CIK 0001104506 and trades as INSM.
- Who audits INSMED Inc?
- Ernst & Young LLP, Iselin, New Jersey, as named in its latest annual report (10-K).
- How many shares of INSMED Inc are outstanding?
- 219.4 million shares as of October 23, 2026, from its 10-Q filed October 29, 2026.
- What is INSMED Inc's public float?
- $21.1B as of June 30, 2025, as reported on the cover of its 10-K filed February 19, 2026.
- How many business segments does INSMED Inc report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed October 29, 2026.
- When is INSMED Inc's annual shareholder meeting?
- May 13, 2026, per its proxy statement (DEF 14A) filed April 1, 2026.
- Have INSMED Inc insiders traded stock recently?
- Since January 8, 2026, officers and directors reported 44 open-market sales worth about $99.8M and 0 purchases on Forms 4 and 5. The most recent: David R. Brennan (Director) sold 25,000 shares on September 9, 2026.